Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview of Protein Metabolism01:21

Overview of Protein Metabolism

1.8K
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
1.8K
Muscle Recovery and Fatigue01:24

Muscle Recovery and Fatigue

2.5K
Muscle fatigue refers to the decline in a muscle's ability to maintain the force of contraction after prolonged activity. It primarily stems from changes within muscle fibers. Even before experiencing muscle fatigue, one may feel tired and have the urge to stop the activity. This response, known as central fatigue, occurs due to changes in the central nervous system, namely the brain and spinal cord. While there is no single mechanism that induces fatigue, it may serve as a protective...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Macrophage-Myocyte Cross Talk Induces M1 Polarization and Inflammatory Cytokine Production During Cancer Cachexia.

Mediators of inflammation·2026
Same author

Synergism of commercialized miticides by trans-chrysanthemic acid (TCA) to the parasitic mite, Varroa destructor.

Pesticide biochemistry and physiology·2026
Same author

Water-based UV-ozone activation enables aggregation-free processing of MFI nanosheets for membrane fabrication.

Nature communications·2026
Same author

From Bureaucracy to Startups: How Workplace Bullying Is Talked About on Online Employee Communities.

Cyberpsychology, behavior and social networking·2026
Same author

Internal defect database of mechanically deformed ferritic steel via X-ray computed tomography.

Scientific data·2025
Same author

Predicting and explaining recurrent child abuse using interpretable machine learning: Evidence from national-level child abuse data in South Korea (2017-2020).

Social science & medicine (1982)·2025

Related Experiment Video

Updated: Sep 11, 2025

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

16.5K

Alpha-Ketoisocaproate Attenuates Muscle Atrophy in Cancer Cachexia Models.

Pooreum Lim1, Sang Woo Woo1, Jihye Han1

  • 1Department of Anatomy, Korea University College of Medicine, Seoul, Republic of Korea.

Journal of Cachexia, Sarcopenia and Muscle
|August 14, 2025
PubMed
Summary

Alpha-ketoisocaproate (KIC) effectively combats cancer-associated cachexia (CAC) muscle atrophy by targeting myostatin. This study shows KIC improves muscle function and mass, offering a potential therapeutic strategy for CAC.

Keywords:
AktFoxO3aalpha‐ketoisocaproatecancer cachexiamyostatinprotein turnover

More Related Videos

Author Spotlight: Advanced Integrated Model for Sepsis-Induced Myopathy and Single-Cell Metabolic Analysis
04:01

Author Spotlight: Advanced Integrated Model for Sepsis-Induced Myopathy and Single-Cell Metabolic Analysis

Published on: June 14, 2024

938
Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
12:59

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

12.7K

Related Experiment Videos

Last Updated: Sep 11, 2025

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

16.5K
Author Spotlight: Advanced Integrated Model for Sepsis-Induced Myopathy and Single-Cell Metabolic Analysis
04:01

Author Spotlight: Advanced Integrated Model for Sepsis-Induced Myopathy and Single-Cell Metabolic Analysis

Published on: June 14, 2024

938
Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
12:59

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

12.7K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Cancer-associated cachexia (CAC) is a debilitating condition characterized by muscle mass loss, with limited treatment options.
  • While L-leucine and HMB show promise, the therapeutic potential of KIC, a leucine metabolite, for CAC remains largely unexplored.

Purpose of the Study:

  • To investigate the efficacy of alpha-ketoisocaproate (KIC) as a therapeutic agent for muscle atrophy in cancer-associated cachexia (CAC).
  • To elucidate the underlying molecular mechanisms, particularly the role of myostatin and the Akt-FoxO3a pathway.

Main Methods:

  • Utilized mouse models (BALB/c) and cell cultures (C2C12 myotubes) to simulate C26 and 4T1 induced CAC.
  • Administered KIC and measured muscle strength, mass, myostatin expression, and downstream signaling pathways (Akt-FoxO3a).

Main Results:

  • KIC significantly suppressed myostatin mRNA and protein expression more effectively than L-leucine.
  • KIC treatment improved myotube diameter, fusion index, and protein turnover, while reducing atrophy markers (MuRF1, MAFbx) in a myostatin-dependent manner.
  • In vivo, KIC administration notably increased body weight, grip strength, and skeletal muscle mass in tumor-bearing mice, while reducing serum myostatin levels.

Conclusions:

  • KIC demonstrates significant potential as a therapeutic agent for muscle atrophy in CAC.
  • The mechanism involves regulating myostatin expression via the Akt-FoxO3a pathway, leading to improved muscle function and mass.